Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection

Transfusion

Volumn 46, Issue 11, 2006, Pages 1886-1891

  Nübling, C Micha ^a   Chudy, Michael ^a   Volkers, Peter ^a   Löwer, Johannes ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B CORE ANTIGEN; NEOPTERIN; VIRUS ANTIGEN;

ARTICLE; BLOOD DONOR; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE AMPLIFICATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE ANALYSIS; SEROCONVERSION;

ALANINE TRANSAMINASE; BLOOD DONORS; DNA, VIRAL; DONOR SELECTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEOPTERIN; POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 33750354876     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00994.x     Document Type: Article

References (26)

1. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002;3:175-87.
2. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 1992;29:307-41.
3. Schennach H, Mayersbach P, Schonitzer D, et al. Increased prevalence of IgM antibodies to Epstein-Barr virus and parvovirus B19 in blood donations with above-normal neopterin. Clin Chem 1994;40:2104-5.
4. Honlinger M, Fuchs D, Reibnegger G, et al. Neopterin screening and acute cytomegalovirus infections in blood donors. Clin Invest 1992;70:63.
5. Schennach H, Hessenberger G, Mayersbach P, Schonitzer D, Fuchs D. Acute cytomegalovirus infections in blood donors are indicated by increased serum neopterin concentrations. Med Microbiol Immunol (Berl) 2002;191:115-8.
6. Schennach H, Lanthaler AJ, Mayersbach P, et al. Human parvovirus Bb19 detection in asymptomatic blood donors: association with increased neopterin concentrations. J Infect Dis 2002;186:1494-7.
7. Babb K, Carrington CV, Monteil MA. A preliminary study of neopterin as a potential marker for severe dengue virus infection. Trans R Soc Trop Med Hyg 1999;93:447-8.
8. Zaknun D, Weiss G, Glatzl J, Wachter H, Fuchs D. Neopterin levels during acute rubella in children. Clin Infect Dis 1993;17:521-2.
9. Murr C, Bergant A, Widschwendter M, et al. Neopterin is an independent prognostic variable in females with breast cancer. Clin Chem 1999;45:1998-2004.
10. Samsonov M, Nassonov E, Dhzuzenova B, et al. Serum neopterin in acute rheumatic fever. Clin Chem 1993;39:693-5.
11. Roth WK, Weber M, Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999;353:359-63.
12. Nubling CM, Chudy M, Lower J. Validation of HCV-NAT assays and experience with NAT application for blood screening in Germany. Biologicals 1999;27:291-4.
13. Honlinger M, Fuchs D, Hausen A, et al. [Serum neopterin determination for the additional safeguarding of blood transfusions. Our experiences with 76,587 blood donors]. Dtsch Med Wochenschr 1989;114:172-6.
14. Zangerle R, Schonitzer D, Fuchs D, et al. Reducing HIV transmission by seronegative blood. Lancet 1992;339:130-1.
15. Gaines H, von Sydow MA, von Stedingk LV, et al. Immunological changes in primary HIV-1 infection. AIDS 1990;4:995-9.
16. Nubling CM, Unger G, Chudy M, Raia S, Lower J. Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 2002;42:1037-45.
17. Westermann J, Thiemann F, Gerstner L, et al. Evaluation of a new simple and rapid enzyme-linked immunosorbent assay kit for neopterin determination. Clin Chem Lab Med 2000;38:345-53.
18. Laich A, Neurauter G, Wirleitner B, Fuchs D. Degradation of serum neopterin during daylight exposure. Clin Chim Acta 2002;322:175-8.
19. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-90.
20. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;351:760-8.
21. Roth WK, Weber M, Petersen D, et al. NAT for HBV and anti-HBc testing increase blood safety. Transfusion 2002;42:869-75.
22. Offergeld R, Faensen D, Ritter S, Hamouda O. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-02: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill 2005;10:8-11.
23. Commission Decision of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (2202/364/EC). Off J Eur Commun 2002;L131:17-30.
24. Mildvan D, Spritzler J, Grossberg SE, et al. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis 2005;40:853-8.
25. Wirleitner B, Schroecksnadel K, Winkler C, Fuchs D. Neopterin in HIV-1 infection. Mol Immunol 2005;42:183-94.
26. Grungreiff K, Reinhold D, Ansorge S. Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha. Cytokine 1999;11:1076-80.